RTTR raised $20m at $5 PPS($2.25 current)."The initial public offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial public offering price of $5.00 per share, for aggregate gross proceeds to us of $20 million".
RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. http://www.ritterpharmaceuticals.com/investors/overview
10Q: "The majority of our research and development resources are focused on the Phase 2b and Phase 3 RP-G28 trials and our other planned clinical and nonclinical studies and other work needed to submit RP-G28 for the reduction of symptoms associated with lactose intolerance in patients for regulatory approval in the United States and Europe. We have incurred and expect to continue to in cur expenses in connection with these efforts, including:
•conduct our Phase 2b/3 clinical trials as an adaptive design Phase 2b/3 clinical trials; • working with our CRO to prepare for launch of the Phase 2b/3 and Phase 3 trials; • and working with our third-party drug formulator to produce sufficient drug product for the adaptive design Phase 2b/3 clinical trials and other contemplated trials".
8 new positions(including Bakers Bros new stake,400k shares) vs 0 Decreased Positions http://www.nasdaq.com/symbol/rttr/institutional-holdings Market value,Share Structure, Cash and Debt: As of August 4, 2015, there were 7,792,433 shares,so Market cap is about than $17m.
10Q: Cash $19.6M VS Total current liabilities - $2.3m (very solid ratio)
Market Data 
Markets 
AI
